(Bloomberg) -- China’s economic offensive against Australia is partly designed to warn countries against vocally opposing Beijing’s interests, particularly with Joe Biden looking to unite U.S. allies. Yet it’s already showing signs of backfiring.China last week imposed anti-dumping duties of up to 212% on Australian wine, the latest in a slew of measures curbing imports from coal to copper to barley. Tensions escalated further on Monday after a Chinese Foreign Ministry official tweeted a fake photo of an Australian soldier holding a knife to the throat of an Afghan child.Australian Prime Minister Scott Morrison quickly called on China to apologize for the “repugnant” tweet. China’s Foreign Ministry spokesperson Hua Chunying, in turn, questioned whether he lacks “a sense of right and wrong” and said overall ties deteriorated because Australia “took wrong measures on issues bearing on China’s core interests.”To Beijing, the attacks on Australia are meant to deter others like Canada, the European Union and Japan from joining a U.S.-led campaign to counter China’s rise. Communist Party officials see Morrison’s government as one of their most vocal critics, and an easy target: China accounts for about 35% of Australia’s total trade, three times more than the next highest country, Japan. Australia accounts for less than 4% of China’s commerce.“It is only natural that China wants to sound some precautionary alarm” to warn countries off building an anti-China alliance, said Zhu Feng, professor of international relations at Nanjing University. “After all, confrontation is the least wanted by the world now.”China is betting that most Western countries will avoid provoking Beijing and risking the kind of trade retaliation Australia is suffering, particularly with their economies weighed down by the pandemic. At the same time, it has sought to strengthen ties with Japan, South Korea and nations in Southeast Asia, in part by offering more trade, investment in 5G networks and access to Covid-19 vaccines.Yet China’s moves are adding to worries about its use of economic coercion, and could end up pushing middle powers closer to the U.S. camp. President-elect Biden has vowed to rebuild relationships with allies damaged by Donald Trump’s “America First” policies, which in turn would make it more palatable for some allies to align more closely with his administration.“Biden is planning is to resume U.S. international policy after a four-year hiccup,” said Jeff Moon, the U.S.’s assistant trade representative for China for part of the Obama administration, adding that the scope of China’s actions against Australia was “breathtaking.”“The leverage is to work together,” he added. “That is what they most fear, and they see that coming.”While it’s still unclear how exactly that would work, several key groupings including the Quad -- the U.S., Japan, Australia and India -- as well as Five Eyes -- the U.S., Australia, U.K., Canada and New Zealand -- have been revived in recent years. New initiatives have also been floated, including one that would give countries an alternative to Huawei Technologies Co. for 5G networks and another that would find alternative supply chains to China.The Wall Street Journal reported in November that the Trump administration was formulating a joint retaliation plan that would allow the West to push back against the kind of economic coercion China is inflicting on Australia. The European Union also plans to call on the U.S. to seize a “once-in-a-generation” opportunity to forge a new global alliance that would counter China, the Financial Times reported Monday, citing a set of draft policy proposals.For its part, the Trump administration is continuing to pressure China with moves to prevent some of its biggest companies from accessing American technology. Senior officials have also stepped up visits to Asia ahead of the planned inauguration for Biden on Jan. 20: Following a visit to Japan in November, National Security Adviser Robert O’Brien said leaders in Tokyo saw the Quad as a “game changer.”“China against any individual country, including quite powerful countries like South Korea or Thailand or even Japan, China would be dominant,” said Malcolm Rifkind, a former British foreign secretary. “But in the real world when you have such a situation, your potential victims join up to ensure a collective and coordinated response.”‘Evil’ AustraliaPart of China’s aggressive response is for a domestic audience. State news agency Xinhua carried a commentary that called Morrison’s request for an apology “utterly absurd,” while the Communist Party’s Global Times called Australia “evil” in an editorial. Social media users on Weibo and Wechat commended Hua, the Foreign Ministry spokesperson, for exuding the “style of a great power” in her responses to repeated questions by foreign journalists. Beijing has also sought to distinguish between countries that step out of line, in effect playing them off each other. Earlier this year the Global Times said China should deliver “public and painful” retaliation to the U.K. for banning Huawei but avoid a full-fledged confrontation because it saw Britain as the “weak link” in the Five Eyes.In a phone call with his EU counterpart Josep Borrell last week, Chinese Foreign Minister Wang Yi also signaled the bloc should think twice before strengthening ties with the incoming Biden administration, as the two sides look to complete an investment treaty by the end of the year. “Strategic autonomy is a necessary character for staying independent,” Wang said, adding that it involves “opposing man-made ‘decoupling’, opposing confrontation among different blocs and a new ‘Cold War.’”Australia, on the other hand, has faced China’s unabashed wrath ever since Morrison’s government called for Beijing to allow independent investigators into Wuhan to discover the origins of Covid-19. Chen Hong, director of the Australian Studies Centre at East China Normal University who said he had his visa to Australia revoked this year because he was labeled a national security risk, said Australia’s actions differentiated it from New Zealand, which maintained relatively good ties with Beijing.“Australia has been purposefully echoing the Washington’s anti-China policy and coordinated with Trump’s strategic intentions,” Chen said.Allies GalvanizedStill, in an early sign that Beijing’s Afghan tweet may have galvanized some of Australia’s partners into responding, New Zealand Prime Minister Jacinda Ardern said on Tuesday that her own diplomats had directly registered concern with Chinese authorities over the “unfactual post.” Lawmakers in the U.K. also condemned China’s actions, with former Conservative party leader Iain Duncan Smith urging Britain to do more to stand with Australia, the Sydney Morning Herald reported.In Canberra, Australian officials have said Morrison’s government is speaking out for its own interests regardless of the U.S. on issues like China’s increasing grip over Hong Kong and assertiveness in the South China Sea. Morrison himself has also sought to portray Australia as stuck in the middle of the U.S. and China -- a view also shared by Singapore Prime Minister Lee Hsien Loong, who said in an interview in November that many nations in Asia aren’t keen to join an anti-China bloc.Even after he called on China to apologize for the Afghan tweet on Monday, Morrison again sought to restart talks with Beijing without conditions.“Countries around the world are watching this, they are seeing how Australia is seeking to resolve these issues and they are seeing these responses,” Morrison told reporters on Monday. “This impacts not just on the relationship here, but with so many other sovereign nations not only in our own region, but like-minded countries around the world.”The spat has only hardened attitudes toward China within Australia, to the point where even business groups have stopped pushing for warmer ties, according to Natasha Kassam, a former Australian diplomat who worked in China and is now a research fellow at the Sydney-based Lowy Institute. At the same time, she said, it’s “impossible to imagine” China apologizing to Australia.“While there may be an emboldening of countries in the region responding to China,” she said, “it’s equally likely that a number of countries will see the way in which Australia’s export industry has been punished and think twice about making their own criticisms.”(Updates with Chinese domestic media reaction in 14th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Standing outside the hospital morgue, Lourdes Visus Cedrian shivered as she remembered the endless procession of hearses pulling up to collect the dead Covid-19 patients she'd been nursing just hours before.
The 26-year-old's body had no visible signs of injury, with her mother convinced her daughter was murdered.
The Aircraft Cleaning Chemicals Market will grow by USD 359.90 mn during 2020-2024
Sunnova Announces Pricing of Primary and Secondary Offering of Shares of Common Stock
CALGARY, Alberta, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.WT, SUGR.WS, SUGR.DB) ("Sugarbud") is pleased to announce the filing of its Q3 2020 unaudited condensed consolidated interim financial statements (“Financial Statements”) for the three and nine months ended September 30, 2020 and related management’s discussion and analysis (“MD&A”). Sugarbud’s Financial Statements and related MD&A are available on SEDAR at www.sedar.com and on Sugarbud's website at www.sugarbud.ca. “In Q3 2020, Sugarbud achieved numerous key milestones in our commercial scale-up and growth plans,” stated Sugarbud CEO John Kondrosky. “In addition to receiving our amended sales license for dried cannabis - which we view as a critical enabling catalyst for growth - the Company also secured supply agreements with the Provinces of Saskatchewan and Alberta.”“Furthermore, in early Q4 we signed a supply agreement with the Province of British Columbia – giving Sugarbud access to the entire Western Canadian retail distribution network. Q3 also saw Sugarbud shipping its first orders.” “With a significant uptick in purchase orders since the end of the quarter, we are very pleased with our progress to date and believe that we have established a strong commercial foundation for future growth heading into 2021,” concluded Mr. Kondrosky.About SugarbudSugarbud is an Alberta-based, consumer-driven craft cannabis company focused on the cultivation and production of superior, select-batch, craft cannabis products. Our vision and mission are to become a trusted and well-respected consumer brand renowned for providing exceptional high-quality craft cannabis products to legal markets by delighting the most discerning of cannabis consumers. http://www.sugarbud.ca/ John Kondrosky Chief Executive Officer Sugarbud Craft Growers Corp. Phone: (604) 499-7847 E-mail: firstname.lastname@example.org Investor Relations Contact Chris Moulson Chief Financial Officer Sugarbud Craft Growers Corp. Tel: (778) 388-8700 E-mail: email@example.comWebsites: http://www.sugarbud.ca/ http://craftcannabiscollection.caAddress: Suite 620, 634 - 6th Avenue S.W., Calgary, Alberta T2P 0S4Forward Looking and Cautionary Statements This news release contains forward-looking statements. More particularly, and without limitation, this news release contains statements concerning: Sugarbud's assessment of future plans, operations and cannabis cultivation, including sales, marketing and distribution opportunities; the Company's ability to remain operating in accordance with developing public health efforts to contain COVID-19. When used in this document, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by Sugarbud. Forward-looking statements are subject to a wide range of risks and uncertainties, and although Sugarbud believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to: currently contemplated expansion and development plans may cease or otherwise change; production of cannabis may be lower than expected; ability to ship cannabis products may be lower than expected; demand for Sugarbud's products may be lower than anticipated; results of production and sale activities; results of scientific research; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; failure to maintain consumer brand recognition and loyalty of customers; reliance on relationships with wholesalers and retailers for distribution of products and failure to maintain strategic business relationships; intense competition, including from illicit sources; uncertainty and continued evolution of markets; product liability litigation; reliance on information technology; infringement on intellectual property; failure to benefit from partnerships; sensitivity of end-customers to increased sales taxes and economic conditions; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; actions and initiatives of federal and provincial governments and changes to government actions, initiatives and policies and the execution and impact thereof; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; the size of the medical marijuana market and the recreational marijuana market; government regulations, including future legislative and regulatory developments involving medical and recreational marijuana; construction delays; risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks which can have a significant impact on the size and quality of the harvest of cannabis crops; competition from other industry participants; and other factors more fully described from time to time in the reports and filings made by Sugarbud with securities regulatory authorities. In addition, the Company cautions that current global uncertainty with respect to the spread of the COVID-19 virus and its effect on the broader global economy may continue to have a significant negative effect on the Company. While the precise impact of the COVID-19 virus on the Company remain unknown, rapid spread of the COVID-19 virus may continue to have a material adverse effect on global economic activity, and can result in volatility and disruption to global supply chains, operations, mobility of people and the financial markets, which could affect interest rates, credit ratings, credit risk, inflation, business, financial conditions, results of operations and other factors relevant to the Company. Please refer to Sugarbud's most recent annual information form and management's discussion and analysis for additional risk factors relating to Sugarbud, which can be accessed under Sugarbud's profile on www.sedar.com. Except as required by applicable laws, Sugarbud does not undertake any obligation to publicly update or revise any forward-looking statements.Neither the TSXV nor its regulation services provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Pablo Matera has been stood down as Argentina's rugby captain over explosive comments he made several years ago.
The Extremities Market will grow by $ 2.93 bn during 2020-2024
On November 23 local time, the news conference for launching of Lianhua Qingwen Capsules, a Chinese traditional medicine produced by Yiling Pharmaceutical, was held online. It signifies that Lianhua Qingwen has officially come into the Philippine market for sale, providing the nation with a traditional Chinese medicine (TCM) solution for respiratory diseases including COVID-19, cold and flu.
Innovative company invests to make Connected Packaging a reality for brands of all sizesAustin, Texas USA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- ePac Flexible Packaging, the industry leader in digitally printed flexible packaging, has announced the appointment of Ryan Kiley to the position of Director, Market Development responsible for driving ePac’s connected packaging solution - ePacConnect on a global basisIn his most recent assignment, Mr. Kiley was with Ricoh North America for 13 years, and responsible for building the company’s production-class Software and Professional Service business unit. Previously, he spent 10 years with Rochester Software Associates as Director of Professional Services. Throughout Ryan’s career, he has successfully driven the development, sale, and services of digital print enabling software. According to Carl Joachim, ePac's CMO: “To drive the market development of ePacConnect, we needed someone with a proven track record of success in software and professional services around production digital printing technologies. We’re excited to have Ryan on board to bring the capabilities of digitally produced connected packaging to our customers.”ePacConnect leverages the power of digital printing to create serialized, trackable flexible packaging and new ways for brands to engage consumers, gain market insights and protect their brand. ePac will offer all its customers an entry-level no-cost solution, ideal for small and medium-sized brands, as well as a subscription fee-based solution for customers with broader requirements. By serializing each package it is automatically digitally enabled, given a unique digital identity, and can be “activated” at any time to give brands flexibility for how and when the codes are used. ePacConnect is currently being piloted in the United States and Europe with a full roll-out to all ePac locations planned in early 2021. About ePac Flexible PackagingePac’s founders began with a mission to provide locally-based consumer packaged goods companies the ability to compete with large brands with great packaging. ePac’s customers are predominantly local/regional small and medium-sized CPGs, many of whom are focused on creating natural and innovative products for consumers. Since opening its first manufacturing facility in 2016, ePac’s mission has been clear – to help small brands obtain big brand presence, give back to the communities it serves, and contribute to the creation of a more sustainable, circular economy. Attachments * Ryan Kiley Press Release (1) * ePacConnect Press Release - 10_21_20 (2) CONTACT: Carl Joachim ePac Flexible Packaging +1 561-573-7992 cjoachim@ePacFlexibles.com
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the pricing of the previously announced public offering of 54,500,000 shares of its common stock held by Bayer World Investments B.V, an affiliate of Bayer AG, at $30.25 per share. Bayer World Investments B.V. is the sole selling shareholder and has also granted to the underwriters an option to purchase up to an additional 8,175,000 shares of common stock. Elanco will not issue shares in the offering and will not receive any proceeds from the sale of the shares by the selling shareholder in the offering. The offering is expected to close on or about December 3, 2020, subject to certain customary closing conditions.
Asian markets rose Tuesday as investors resumed their vaccine-fuelled buying spree, though gains were kept in check by the spectre of surging virus infections.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980. The investigation concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On November 4, 2020, bluebird disclosed that the Company will no longer be applying for U.S. Food and Drug Administration (“FDA”) approval of its bb1111 product as a treatment for sickle cell disease in the second half of 2021 as expected. Instead, citing “feedback” from the FDA, “alongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts, bluebird is adjusting its submission timing to late 2022.”On this news, bluebird’s stock price fell $12.66 per share, or 21.62%, over the following two trading sessions, to close at $45.89 per share on November 6, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP email@example.com 888-476-6529 ext. 7980
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX / TSX: CDV) (“Cardinal” or “the Company”) is pleased to announce the results of the Company’s Annual General Meeting held today in Australia (the “Meeting”). At the Meeting, proxies representing 203,582,834 shares were received, representing approximately 38% of the shares eligible for voting at the Meeting as of the record date. All matters presented for approval at the Meeting by management of the Company were duly authorized and approved. The resolutions approved included the advisory resolution approving the Remuneration Report, re-election of management nominees to the board of directors of the Company (“Board”) that were due for election and the ratification of the Company's prior issue of shares.Detailed voting results regarding the election of directors are as follows:NameOutcome of VoteShares Voted ForVotes For %Shares WithheldVotes Withheld % Michele MuscilloElected166,667,49481.9936,618,85318.01 Malik EasahElected166,398,49481.9636,617,85318.04 In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the following information is provided to the Australian Securities Exchange in relation to resolutions passed by members of Cardinal.Resolution Decided by a show of hands (S) or poll (P) Total number of proxy votes exercisable by proxies validly appointed Total number of proxy votes in respect of which the appointments specified that: - The proxy is to vote for the resolutionThe proxy is to vote against the resolutionThe proxy is to abstain/excluded on the resolutionThe proxy may vote at the proxy’s discretion 1P199,793,895161,946,30536,619,8031,227,7870 2P203,582,834166,667,49436,618,853296,4870 3P203,312,834166,398,49436,617,853296,4870 4P135,092,93296,588,05237,754,274750,6060 Note: Resolution numbers in this table refer to the resolution numbers in the Notice of Annual General Meeting dated October 16, 2020.Further details on the matters voted upon at the Meeting can be found in the Company’s Meeting materials, including the management information circular dated October 16, 2020, which are accessible under the Company's SEDAR profile at www.sedar.com. The Company has also filed a report of voting results on all resolutions voted on at the Meeting on SEDAR.ABOUT CARDINALCardinal Resources Limited (ASX/TSX: CDV) is a West African gold‐focused exploration and development Company that holds interests in tenements within Ghana, West Africa.The Company is focused on the development of the Namdini Gold Project and released its Feasibility Study on 28 October 2019.Cardinal confirms that it is not aware of any new information or data that materially affects the information included in its announcement of the Ore Reserve of April 3, 2019. All material assumptions and technical parameters underpinning this estimate continue to apply and have not materially changed.*The Namdini Project has a published gold Ore Reserve of 5.1 Moz (138.6 Mt @ 1.13 g/t Au; 0.5 g/t cut-off), inclusive of 0.4 Moz Proved (7.4 Mt @ 1.31 g/t Au; 0.5 g/t cut-off) and 4.7 Moz Probable (131.2 Mt @ 1.12 g/t Au; 0.5 g/t cut-off). Authorised for release by the Board of Cardinal Resources Limited.For further information contact:Sarah Shipway Company Secretary Cardinal Resources Limited P: +61 8 6558 0573 E: firstname.lastname@example.org
Plans made by the National Disability Insurance Scheme need to be more transparent, consistent and accurate, a parliamentary committee has found.
A South Australian man has been jailed for at least 20 years over a killing that was sparked by a desire to plunder his victim's bank account.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 6, 2020, Molecular Templates disclosed that the U.S. Food and Drug Administration (“FDA”) had placed the Company’s “MT-3724 clinical studies on partial clinical hold following a treatment-related fatality in one subject who experienced Grade 5 capillary leak syndrome in the Phase 2 MT-3724 monotherapy study in in relapsed/refractory diffuse large B-cell lymphoma patients.” Molecular Templates advised investors that the Company “is working to address the clinical and MT-3724 product lot information requests from the FDA and will then seek agreement from FDA to remove the partial clinical hold.” On this news, Molecular Templates’ stock price fell $2.30 per share, or 21.18%, to close at $8.56 per share on November 6, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
New Zealand's health ministry is investigating whether three touring Pakistan cricketers were infectious when they produced positive tests to COVID-19.
Edinson Cavani showed why Manchester United handed the veteran Uruguayan the bumper two-year contract others balked at as he turned defeat into victory at Southampton on Sunday.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Raytheon Technologies Corporation (“Raytheon” or the “Company”) (NYSE: RTX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether Raytheon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On October 27, 2020, Raytheon filed its quarterly report for the third fiscal quarter with the U.S. Securities and Exchange Commission, in which the Company disclosed receipt of a criminal subpoena from the U.S. Department of Justice seeking information and documents in connection with an investigation relating to financial accounting, internal controls over financial reporting, and cost reporting regarding Raytheon’s Missiles & Defense business since 2009. On this news, Raytheon’s stock price fell $4.19 per share, or 7.4%, to close at $52.34 per share on October 28, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980